CAR T-Cell Therapy for Relapsed/Refractory Multiple Myeloma

Joseph Mikhael, MD


April 03, 2023

Several novel cell-based immunotherapies have been introduced in recent years that can significantly improve survival of patients with multiple myeloma. Most recently, two CAR T-cell therapies, idecabtagene vicleucel (ida-cel) and ciltacabtagene autoleucel (cilta-cel), were approved for the treatment of multiple myeloma in patients who did not respond to multiple other lines of therapy.

In this ReCAP, Dr Joseph Mikhael, of City of Hope Cancer Center and the International Myeloma Foundation in Phoenix, Arizona, discusses the clinical trials demonstrating response rates for ida-cel and cilta-cel therapies of 81% and 98%, respectively. He also examines the differences between the two, including production time and toxicities, and the factors involved in the choice to use either CAR T-cell therapy.

Finally, he discusses the importance of improving access to new therapies and comments on the future of multiple myeloma treatments, including other potential CAR T-cell targets.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.